ABOUT PROVISTA
Provista Diagnostics is focused on developing world-class diagnostics for indications in breast and gynecological cancers. When used in combination with standard of care, Provista's blood-based diagnostic tests provide real-time actionable results to improve the accuracy of cancer detection.
Read More
SCIENCE & TECHNOLOGY
Provista’s proprietary ProteoMark® Technology combines multiple Serum Protein Biomarkers and Tumor Associated Autoantibodies, with patient clinical data, to yield highly accurate diagnostic tests for women’s cancers.
Read More
DIAGNOSTIC PIPELINE
Provista is developing a robust pipeline of diagnostic blood tests to address unmet needs in women’s cancers including breast, ovarian, endometrial and HPV-associated cancers.
Read More
Diagnostic Dilemma
Dense breast tissue is normal and common among woman and it refers to the appearance of breast tissue on a mammogram. Dense tissue appears white on a mammogram similar to both benign and cancerous lumps leading to both false negative and false positive results.
Read More

NEWS

Sign Up for E-News
December 1, 2015

DEC 1, 2015

Provista Diagnostics Announces Pivotal Clinical Results for Videssa® Breast – A Simple Blood Test for Early and Accurate Breast Cancer Detection Data to be Presented at the 101st Scientific Assembly & Annual Meeting of the Radiological Society of North America NEW YORK, NY – December 1, 2015 – Provista Diagnostics, […]
November 18, 2015

Nov 18, 2015

Provista Diagnostics to Present at the 2015 Canaccord Genuity Medical Technology & Diagnostics Forum NEW YORK, NY – November 18, 2015 – Provista Diagnostics, Inc., today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a corporate overview at the upcoming Canaccord Genuity Medical Technology & Diagnostics […]
September 29, 2015

Sep 29, 2015

Provista Diagnostics Offers Hope for the Early Detection of Breast Cancer in Women with Dense Breasts   NEW YORK, NY – September 29, 2015:  Provista Diagnostics, Inc. today announced that the data from two prospective, randomized, multi-center clinical studies, evaluating a novel blood-based combinatorial protein biomarker assay, received overwhelming support from […]